Small interfering RNAs (siRNAs) are widely used to study gene function and there is general excitement about their potential for therapeutic applications. However, several hurdles, including a lack of specificity, will have to be overcome before it is possible to use siRNAs therapeutically.
siRNAs have multiple types of off-target effects, but there are several methods to help mitigate them.
microRNA-like off-target effects refer to siRNA-induced sequence-dependent regulation of unintended transcripts, through partial sequence complementarity to their 3′ UTRs, to produce false-positive phenotypes. Such off-target effects follow the same dose response as on-target effects and therefore cannot be selectively eliminated by reducing siRNA concentration. Off-target siRNA effects are also species-specific.
microRNA-like off-target effects can be mitigated by siRNA redundancy, siRNA pooling or chemical modification such as 2′-O-methyl modification.
A significant obstacle to the therapeutic application of RNAi is the ability of siRNAs and/or their delivery vehicles (such as cationic lipids) to stimulate the innate immune system and trigger an inflammatory response through activation of Toll-like receptors. Immunostimulatory siRNAs can also produce unwanted toxicities, including elevated levels of serum alanine and aspartate aminotransaminases, and reduced numbers of lymphocytes and platelets.
Immunostimulation by siRNAs can be reduced by sequence selection or chemical modification such as substitution of the 2′ position of ribose with 2′-O-methyl, 2′-fluoro, 2′-deoxy or locked nucleic acid.
A novel non-specific effect of RNAi expression relates to saturation of the RNAi machinery; exogenous siRNAs can saturate the endogenous RNAi machinery causing widespread effects on microRNA processing and function.
Understanding the sources of siRNA off-target activity is yielding insights into siRNA design and chemical modification. Much progress has been made in the design of effective siRNAs with reduced off-target liabilities and continued research in this area will undoubtedly lead to further improvements in the development of siRNAs for therapeutic applications.
Small interfering RNAs (siRNAs) are widely used to study gene function owing to the ease with which they silence target genes, and there is considerable interest in their potential for therapeutic applications. In a remarkably short time since their discovery, siRNAs have entered human clinical trials in various disease areas. However, rapid acceptance of the use of siRNAs has been accompanied by recognition of several hurdles for the technology, including a lack of specificity. Off-target activity can complicate the interpretation of phenotypic effects in gene-silencing experiments and can potentially lead to unwanted toxicities. Here, we describe the types of off-target effects of siRNAs and methods to mitigate them, to help enable effective application of this exciting technology.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415–419 (2003).
Lee, Y., Jeon, K., Lee, J. T., Kim, S. & Kim, V. N. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21, 4663–4670 (2002).
Zeng, Y. & Cullen, B. R. Sequence requirements for micro RNA processing and function in human cells. RNA 9, 112–123 (2003).
Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E. & Kutay, U. Nuclear export of microRNA precursors. Science 303, 95–98 (2004).
Yi, R., Qin, Y., Macara, I. G. & Cullen, B. R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011–3016 (2003).
Grishok, A. et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106, 23–34 (2001).
Hutvagner, G. et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293, 834–838 (2001).
Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).
Carthew, R. W. & Sontheimer, E. J. Origins and Mechanisms of miRNAs and siRNAs. Cell 136, 642–655 (2009).
Hamilton, A. J. & Baulcombe, D. C. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286, 950–952 (1999).
Hammond, S. M., Bernstein, E., Beach, D. & Hannon, G. J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 293–296 (2000).
Ketting, R. F. et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15, 2654–2659 (2001).
Knight, S. W. & Bass, B. L. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 293, 2269–2271 (2001).
Parrish, S., Fleenor, J., Xu, S., Mello, C. & Fire, A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell 6, 1077–1087 (2000).
Zamore, P. D., Tuschl, T., Sharp, P. A. & Bartel, D. P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25–33 (2000).
Elbashir, S. M., Lendeckel, W. & Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188–200 (2001).
Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W. & Tuschl, T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20, 6877–6888 (2001).
Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563–574 (2002).
Nykanen, A., Haley, B. & Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107, 309–321 (2001).
Schwarz, D. S., Hutvagner, G., Haley, B. & Zamore, P. D. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell 10, 537–548 (2002).
Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589–595 (2003).
Caplen, N. J., Parrish, S., Imani, F., Fire, A. & Morgan, R. A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl Acad. Sci. USA 98, 9742–9747 (2001).
Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E. & Prydz, H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res. 30, 1757–1766 (2002).
Hutvagner, G. & Zamore, P. D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056–2060 (2002).
Tuschl, T., Zamore, P. D., Lehmann, R., Bartel, D. P. & Sharp, P. A. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13, 3191–3197 (1999).
Chi, J. -T. et al. Genomewide view of gene silencing by small interfering RNAs. Proc. Natl Acad. Sci. USA 100, 6343–6346 (2003).
Semizarov, D. et al. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl Acad. Sci. USA 100, 6347–6352 (2003).
Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotech. 21, 635–637 (2003).
Jackson, A. L. et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179–1187 (2006).
Birmingham, A. et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nature Methods 3, 199–204 (2006).
Brennecke, J., Stark, A., Russell, R. B. & Cohen, S. M. Principles of microRNA-target recognition. PLoS Biol. 3, e85 (2005).
Farh, K. K. et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310, 1817–1821 (2005).
Grun, D., Wang, Y. L., Langenberger, D., Gunsalus, K. C. & Rajewsky, N. microRNA target predictions across seven Drosophila species and comparison to mammalian targets. PLoS Comput. Biol. 1, e13 (2005).
Krek, A. et al. Combinatorial microRNA target predictions. Nature Genet. 37, 495–500 (2005).
Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. Cell 115, 787–798 (2003).
Lim, L. P. et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433, 769–773 (2005).
Stark, A., Brennecke, J., Russell, R. B. & Cohen, S. M. Identification of Drosophila microRNA targets. PLoS Biol. 1, E60 (2003).
Xie, X. et al. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 434, 338–345 (2005).
Lai, E. C. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nature Genetics 30, 363–364 (2002).
Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855–862 (1993).
Lim, L. P. et al. The microRNAs of Caenorhabditis elegans. Genes Dev. 17, 991–1008 (2003).
Wang, Y. et al. Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature 456, 921–926 (2008).
Persengiev, S. P., Zhu, X. & Green, M. R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10, 12–18 (2004).
Jackson, A. L. et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA 12, 1197–1205 (2006). The first study to demonstrate that selective chemical modification of the siRNA guide strand could reduce microRNA-like off-target effects.
Lin, S. et al. siRNA-mediated off-target gene silencing triggered by a 7nt complementation. Nucleic. Acids Res. 33, 4527–4535 (2005).
Whither RNAi? Nature Cell Biol. 5, 489–490 (2003).
Cullen, B. R. Enhancing and confirming the specificity of RNAi experiments. Nature Methods 3, 677–681 (2006).
Echeverri, C. J. et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nature Methods 3, 777–779 (2006). A discussion of siRNA off-target effects and the need for standards of care for validating results from large-scale siRNA studies.
Kittler, R. et al. RNA interference rescue by bacterial artificial chromosome transgenesis in mammalian tissue culture cells. Proc. Natl Acad. Sci. USA 102, 2396–2401 (2005).
Sarov, M. & Stewart, A. F. The best control for the specificity of RNAi. Trends Biotechnol. 23, 446–448 (2005).
Stark, A., Brennecke, J., Bushati, N., Russell, R. B. & Cohen, S. M. Animal microRNAs confer robustness to gene expression and have a significant impact on 3′UTR evolution. Cell 123, 1133–1146 (2005).
Grimson, A. et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91–105 (2007).
Kittler, R. et al. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nature Methods 4, 337–344 (2007).
Burchard, J. et al. MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA 15, 308–315 (2009).
Judge, A. & MacLachlan, I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19, 111–124 (2008). A useful review and guide to manage the immunological effects of siRNAs.
Schlee, M., Hornung, V. & Hartmann, G. siRNA and isRNA: two edges of one sword. Mol. Ther. 14, 463–470 (2006).
Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).
Kariko, K., Bhuyan, P., Capodici, J. & Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172, 6545–6549 (2004).
Sioud, M. & Sorensen, D. R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220–1225 (2003).
Hornung, V. et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263–270 (2005).
Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnol. 23, 457–462 (2005).
Sioud, M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348, 1079–1090 (2005).
Robbins, M., Judge, A. & MacLachlan, I. siRNA and innate immunity. Oligonucleotides 19, 89–102 (2009).
Sledz, C. A., Holko, M., deVeer, M. J., Silverman, R. H. & Williams, B. R. G. Activation of the interferon system by short-interfering RNAs. Nature Cell Biol. 5, 834–839 (2003).
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529–1531 (2004).
Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).
Forsbach, A. et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 180, 3729–3738 (2008).
Goodchild, A. et al. Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol. 10, 40 (2009).
Diebold, S. S. et al. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36, 3256–3267 (2006).
Sioud, M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur. J. Immunol. 36, 1222–1230 (2006).
Kleinman, M. E. et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591–597 (2008). This study shows that the therapeutic activity of certain siRNAs is related to unanticipated class-related vascular or immune effects rather than the intended targets.
Robbins, M. et al. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. 19, 991–999 (2008).
Flynn, M. A., Casey, D. G., Todryk, S. M. & Mahon, B. P. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J. Inflamm (Lond.) 1, 4 (2004).
Ge, Q. et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl Acad. Sci. USA 101, 8676–8681 (2004).
Hamar, P. et al. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 101, 14883–14888 (2004).
Palliser, D. et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89–94 (2006).
Perl, M. et al. Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am. J. Pathol. 167, 1545–1559 (2005).
Reich, S. J. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210–216 (2003).
Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23, 709–717 (2005).
Zender, L. et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl Acad. Sci. USA 100, 7797–7802 (2003).
Armstrong, M. E. et al. Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J. Immunol. 180, 7125–7133 (2008).
Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623–15628 (1998).
Geiss, G. et al. A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J. Biol. Chem. 276, 30178–30182 (2001).
Eberle, F. et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J. Immunol. 180, 3229–3237 (2008). A study showing that suitable chemical modifications can modify the immunological properties of siRNAs without altering their potency by introducing minor structural changes.
Braasch, D. A. & Corey, D. R. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol. 8, 1–7 (2001).
Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol. 23, 1002–1007 (2005).
Judge, A. D., Bola, G., Lee, A. C. & MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494–505 (2006).
Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
Robbins, M. et al. 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15, 1663–1669 (2007).
Yi, R., Doehle, B. P., Qin, Y., Macara, I. G. & Cullen, B. R. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA 11, 220–226 (2005).
Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537–541 (2006).
Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nature Med. 11, 50–55 (2005).
Hutvagner, G., Simard, M. J., Mello, C. C. & Zamore, P. D. Sequence-specific inhibition of small RNA function. PLoS Biol. 2, E98 (2004).
John, M. et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449, 745–747 (2007).
Khan, A. A. et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nature Biotechnol. 27, 549–555 (2009). This study suggests that exogenously added siRNA duplexes displace endogenous microRNAs from RISC complex(s), leading to unintended de-repression of many transcripts.
Aigner, A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J. Biomed. Biotechnol. 2006, 71659 (2006).
Akhtar, S. & Benter, I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164–182 (2007).
Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D. W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chem. Biol. 2, 711–719 (2006).
de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nature Rev. Drug Discov. 6, 443–453 (2007).
Gilmore, I. R., Fox, S. P., Hollins, A. J. & Akhtar, S. Delivery strategies for siRNA-mediated gene silencing. Curr. Drug Deliv. 3, 145–147 (2006).
Gilmore, I. R., Fox, S. P., Hollins, A. J., Sohail, M. & Akhtar, S. The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J. Drug Target 12, 315–340 (2004).
Kim, D. H. & Rossi, J. J. Strategies for silencing human disease using RNA interference. Nature Rev. Genet. 8, 173–184 (2007).
Kuhn, R., Streif, S. & Wurst, W. RNA Interference In Mice. Handb. Exp. Pharmacol., 149–176 (2007).
Leung, R. K. & Whittaker, P. A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107, 222–239 (2005).
Meade, B. R. & Dowdy, S. F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59, 134–140 (2007).
Meade, B. R. & Dowdy, S. F. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv. Drug Deliv. Rev. 60, 530–536 (2008).
Peer, D., Zhu, P., Carman, C. V., Lieberman, J. & Shimaoka, M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl Acad. Sci. USA 104, 4095–4100 (2007).
Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982–12987 (2007).
Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).
Zimmermann, T. S. et al. RNAi-mediated gene silencing in non-human primates. Nature 441, 111–114 (2006).
Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nature Rev. Drug Discov. 8, 129–138 (2009).
Hollins, A. J., Omidi, Y., Benter, I. F. & Akhtar, S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J. Drug Target 15, 83–88 (2007).
Omidi, Y. et al. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target 11, 311–323 (2003).
Omidi, Y., Hollins, A. J., Drayton, R. M. & Akhtar, S. Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J. Drug Target 13, 431–443 (2005).
The authors declare competing financial interests: see web version for details.
- RNA interference
(RNAi). A fundamental pathway in eukaryotic cells by which a short piece of RNA induces the destruction of mRNA(s) with sequence complementarity.
- Small interfering RNA
(siRNA). RNA fragments (typically exogenous), ∼21–23 nt long, that induce the sequence-dependent destruction of complementary mRNA.
Genomically-encoded non-coding RNAs that regulate gene expression through a mechanism that involves the inhibition of translation and transcript degradation.
- Guide strand
The strand of the siRNA or microRNA that is complementary to the target mRNA sequence(s).
- RNA-induced silencing complex (RISC)
A multiprotein complex that incorporates one strand of an siRNA or microRNA as a template for targeting a complementary mRNA and is responsible for the destruction of the target mRNA.
- Seed region
The portion of the guide strand implicated in target recognition; it encompasses positions 1–8 at the 5′ end of the guide strand.
- Lipid nanoparticle
A drug delivery vehicle made of lipids that can encapsulate the siRNA or small molecule for delivery across the cell membrane.
Capable of activating the innate immune response for host defense against invading pathogens.
About this article
Cite this article
Jackson, A., Linsley, P. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9, 57–67 (2010). https://doi.org/10.1038/nrd3010
Frontiers in Physiology (2020)
Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach
International Journal of Molecular Sciences (2020)
Cell Death Discovery (2020)
Cancer Cell (2020)
Current Osteoporosis Reports (2020)